Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial

BACKGROUND: CheckMate 9KD (NCT03338790) is a non-randomized, multicohort, phase 2 trial of nivolumab plus other anticancer treatments for metastatic castration-resistant prostate cancer (mCRPC). We report results from cohorts A1 and A2 of CheckMate 9KD, specifically evaluating nivolumab plus rucapar...

Descripción completa

Detalles Bibliográficos
Autores principales: Fizazi, Karim, Retz, Margitta, Petrylak, Daniel P, Goh, Jeffrey C, Perez-Gracia, Jose, Lacombe, Louis, Zschäbitz, Stefanie, Burotto, Mauricio, Mahammedi, Hakim, Gravis, Gwenaelle, Bastos, Diogo Assed, McCune, Steven L, Vázquez Limón, Juan Carlos, Kwan, Edmond M, Castellano, Daniel, Fléchon, Aude, Saad, Fred, Grimm, Marc-Oliver, Shaffer, David R, Armstrong, Andrew J, Bhagavatheeswaran, Prabhu, Amin, Neha P, Ünsal-Kaçmaz, Keziban, Wang, Xuya, Li, Jun, Loehr, Andrea, Pachynski, Russell K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9389086/
https://www.ncbi.nlm.nih.gov/pubmed/35977756
http://dx.doi.org/10.1136/jitc-2022-004761

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9389086/
https://www.ncbi.nlm.nih.gov/pubmed/35977756
http://dx.doi.org/10.1136/jitc-2022-004761

Ejemplares similares